Investors might want to bet on Kemper (KMPR), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole …
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is …
Investors might want to bet on Scor SE (SCRYY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. …
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …
Investors might want to bet on Palantir Technologies Inc. (PLTR), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. …
Investors might want to bet on Novozymes A/S (NVZMY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The …
Societe BIC Disclosure of total number of voting rights and number of shares forming the capital as of March 31, 2025 CLICHY – April 07, 2025 Article L 233-8-II of the French “Code de Commerce” and Article 223-16 of the General Regulations of the …
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 15 cents in first-quarter 2025, narrower than the year-ago adjusted loss of 26 cents per share. The adjusted loss per share topped the Zacks Consensus Estimate by …
The Carlyle Group Inc. CG reported first-quarter 2025 post-tax distributable earnings per share of $1.14, which topped the Zacks Consensus Estimate of 97 cents. The figure compared favorably with earnings of $1.01 per share in the year-ago quarter. Results benefited from increases in segmental …